JP2020503318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503318A5 JP2020503318A5 JP2019534375A JP2019534375A JP2020503318A5 JP 2020503318 A5 JP2020503318 A5 JP 2020503318A5 JP 2019534375 A JP2019534375 A JP 2019534375A JP 2019534375 A JP2019534375 A JP 2019534375A JP 2020503318 A5 JP2020503318 A5 JP 2020503318A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid
- droxidopa
- liquid composition
- composition according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 23
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2s,3s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 claims 14
- 229960001104 droxidopa Drugs 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000008247 solid mixture Substances 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010063080 Postural orthostatic tachycardia syndrome Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 206010031127 Orthostatic hypotension Diseases 0.000 claims 2
- 239000008297 liquid dosage form Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010022773 Intracranial pressure increased Diseases 0.000 claims 1
- 206010028748 Nasal obstruction Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030302 Oliguria Diseases 0.000 claims 1
- 206010062300 Procedural hypotension Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000012055 enteric layer Substances 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 201000009941 intracranial hypertension Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 208000022084 motor paralysis Diseases 0.000 claims 1
- 230000011224 negative regulation of urine volume Effects 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000001144 postural effect Effects 0.000 claims 1
- 239000011241 protective layer Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438056P | 2016-12-22 | 2016-12-22 | |
| US62/438,056 | 2016-12-22 | ||
| PCT/US2017/068038 WO2018119323A1 (en) | 2016-12-22 | 2017-12-21 | Droxidopa compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503318A JP2020503318A (ja) | 2020-01-30 |
| JP2020503318A5 true JP2020503318A5 (enExample) | 2021-02-04 |
| JP7132924B2 JP7132924B2 (ja) | 2022-09-07 |
Family
ID=62627478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534375A Active JP7132924B2 (ja) | 2016-12-22 | 2017-12-21 | ドロキシドパ組成物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20190321318A1 (enExample) |
| EP (1) | EP3558268B1 (enExample) |
| JP (1) | JP7132924B2 (enExample) |
| WO (1) | WO2018119323A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109726903B (zh) * | 2018-12-19 | 2020-10-16 | 中国电子科技集团公司信息科学研究院 | 基于注意力机制的分布式多智能体协同决策方法 |
| US12409187B2 (en) | 2021-03-31 | 2025-09-09 | Brown University | PH regulating hydrogels that neutralize cancer cell environment acidosis and increase chemotherapy efficacy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001032148A1 (en) * | 1999-10-29 | 2001-05-10 | Euro-Celtique, S.A. | Controlled release hydrocodone formulations |
| WO2004100929A1 (en) * | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
| EP1970040A4 (en) * | 2005-12-22 | 2013-05-29 | Otsuka Pharma Co Ltd | METHOD FOR PRODUCING MEDICINAL WAX MATRIX PARTICLES, IN THE METHOD OF USING EXTRUDERS AND CILOSTAZOL-CONTAINING PREPARATION WITH DELAYED RELEASE |
| US20090143343A1 (en) * | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20120029085A1 (en) * | 2010-07-29 | 2012-02-02 | Mackay Jon | Stabilization of quinol composition such as catecholamine drugs |
| TW201216951A (en) * | 2010-10-21 | 2012-05-01 | Aptalis Pharma Ltd | Oral dosing device for administration of medication |
| JP6007173B2 (ja) * | 2011-04-28 | 2016-10-12 | 株式会社フレッシュ | ボトルキャップおよびこのボトルキャップを有する容器 |
-
2017
- 2017-12-21 JP JP2019534375A patent/JP7132924B2/ja active Active
- 2017-12-21 US US16/472,279 patent/US20190321318A1/en not_active Abandoned
- 2017-12-21 WO PCT/US2017/068038 patent/WO2018119323A1/en not_active Ceased
- 2017-12-21 EP EP17884892.5A patent/EP3558268B1/en active Active
-
2024
- 2024-05-06 US US18/656,105 patent/US20250108026A1/en active Pending